Document:

<PAGE>   1
                                                                   Exhibit 10.47

                              OFFICER'S CERTIFICATE

         I, the undersigned, do hereby certify and represent that:

         1. I am the duly elected Chairman, President and Chief Executive
Officer of deCODE genetics, Inc., a Delaware Corporation.

         2. Pursuant to Rule 306(a) of Regulation S-T, the following exhibit
10.47 to deCODE genetics, Inc.'s Registration Statement on Form S-1 is a fair
and accurate English translation of a document prepared in the Icelandic
language.

         IN WITNESS WHEREOF, I have signed this Officer's Certificate in my
capacity as Chairman, President and Chief Executive Officer of deCODE genetics,
Inc. on this 25th day of April, 2000.

                          By: /s/ Kari Stefansson
                              ------------------------------------
                          Name:   Kari Stefansson
                          Title: Chairman, President and Chief Executive Officer
<PAGE>   2
[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

                    RESEARCH CONTRACT ON THE CO-OPERATION OF
                     A RESEARCH TEAM FOR CHRONIC OBSTRUCTIVE
                                PULMONARY DISEASE
                                       AND
                           ISLENSK ERFDAGREINING EHF

A research team for Chronic Obstructive Pulmonary Disease (hereinafter referred
to as COPD) and related diseases, on the one hand, hereinafter referred to as
RTCOPD, and, on the other hand, Islensk erfoagreining ehf., hereinafter referred
to as IE, enter into the following

                                    Contract

on co-operation on the research of the inheritability of COPD and related
diseases.

This Contract is made on the basis of the Co-operation Agreement between the
State Hospitals and Islensk erfoagreining [e]hf. from 15 December 1998, which
shall prevail over this Contract in the event of any discrepancy between their
individual provisions.

                                    CHAPTER 1
                        THE SUBSTANCE OF THE CO-OPERATION

RTCOPD and IE agree to co-operate, on the basis of this Contract, in the search
for genes involved in the genesis of COPD and related diseases. The proposed
co-operation between the parties will hereinafter be referred to as the Research
Project.

The part of the co-operation involving RTCOPD parties working for the State
Hospitals shall be supervised by the physicians [Foreign Character]orarinn
Gislason and Andres Sigvaldason.

The part of the co-operation involving the National Association for the
Prevention of Heart Diseases, Hjartavernd, [hereinafter referred to as
Hjartavernd) shall be supervised by the physician Vilmundur Guonason.

                                    CHAPTER 2
              CONTRIBUTIONS OF THE PARTIES TO THE RESEARCH PROJECT

2.1 RESEARCH MATERIALS AND THEIR PROCUREMENT
RTCOPD shall provide biosamples (including blood samples and tissue samples),
other clinical data and research materials which RTCOPD may provide, by the
permit of the Data Protection Commission for the research, in relation to
patients suffering from COPD and their relatives who do not suffer from COPD,
cf. Article 5 of this Contract for further details.

RTCOPD shall supervise relations with individuals invited to participate in the
research and/or their legal guardians. This includes procuring the informed
consent of participants, information on health, blood tests or other sampling
and examination of disease symptoms (e.g. further diagnosis). IE, on the one
hand, and RTCOPD and individuals within the team, on the other hand, undertake
to do whatever is in their power so that the procurement of research materials
pursuant to this sub-chapter shall
<PAGE>   3
proceed with expedience and safety. In this respect, account shall be taken of
the Research Plan, which includes milestone dates and is attached to this
Contract as Annex A ('Research Plan and Cost Estimation for the Research of IE
and RTCOPD on COPD'). All research materials delivered to the IE research
laboratory shall first be encrypted at the Genetic Research Service Centre, a
private institution domiciled at Noatun 17, Reykjavik, before being transported
to IE, in accordance with the instructions of the Data Protection Commission.

2.2. EXPERTISE, EQUIPMENT AND RESEARCH FACILITIES
RTCOPD shall provide expertise and knowledge in relation to the diagnosis of
diseases, the design and organisation of the Research Project, the conduct of
experiments and the interpretation of their results.

IE and RTCOPD shall provide expertise for the design and organisation of the
research. IE shall also be responsible for the research and testing of blood
samples and genetic material, the assessment of the inheritance of the disease
and the interpretation of the findings of the research. IE shall, among other
things, provide equipment, research resources, laboratory reagents and personnel
for these purposes.

2.3. PAYMENT OF RESEARCH EXPENSES
IE shall cover all expenses of the Research Project necessary to achieve the
objectives of the Project, including materials and wage costs in relation to
calling in participants for research and necessary sampling.

RTCOPD and IE shall jointly submit a comprehensive budget on signature of this
Contract, in which the projected materials and wage costs of the Project are
estimated, see Annex A. Annex A shall also further delineate the itemisation of
individual cost items and the manner in which the procurement of consent and the
payment of bills shall be conducted. In the event of direct cash outlay on the
part of the State Hospitals in relation to the conduct of this Research Project,
IE and the State Hospitals shall make a special agreement on the payment of such
cost, cf. the Co-operation Agreement between the State Hospitals and Islensk
erfoagreining ehf.

The State Hospitals may request information from IE on wages paid by IE to
employees of the State Hospitals working on the Research Project.

2.4. INTELLECTUAL PROPERTY PROTECTION
RTCOPD and individuals within the team undertake to provide IE with the
assistance necessary to enable IE to ensure international patent protection of
the findings of the Research Project, including application for patents together
with IE when necessary, provided that IE pays all expenses in relation to such
applications.

                                    CHAPTER 3
                              RIGHTS OF THE PARTIES

3.1. THE RIGHTS OF HEALTH-CARE INSTITUTIONS AND THE EFFECTIVE DATE OF THIS
CONTRACT
The parties to this Contract are aware that a framework agreement on the
co-operation Hjartavernd and IE on research into the heredity of certain
diseases is currently in effect. The provisions of the framework agreement
between Hjartavernd and IE are
<PAGE>   4
valid for the part of the Research Project involving Hjartavernd. The framework
agreement between IE and Hjartavernd is attached to this Contract as Annex B.
The parties to this Contract are also aware that a Co-operation Agreement
between IE and the State Hospitals (SH) (hereinafter referred to as the
Institutions Agreement) is currently in effect. The Institutions Agreement
between IE and SH is attached to this Contract as Annex C. The provisions of the
Institutions Agreement shall be valid for this Research Agreement, where
applicable, as regards the part of SH employees. All other payments from IE to
RTCOPD pursuant to chapters 3.3. and 3.4. of this Contract shall be in
accordance with the provisions of Chapter 7.3 of the Institutions Agreement.

3.2. FINANCIAL AND COMMERCIAL RIGHTS ATTACHED TO THE FINDINGS OF THE RESEARCH
PROJECT
IE shall be sole owner of all financial and commercial rights attached to the
Research Project and its results. IE shall have the right to sell the results
and findings of the Research Project to a third party and utilise it financially
in any other way consistent with approved ethical standards, irrespective of
whether this takes place before or after the completion of the Research Project.

IE and its parent company, deCODE genetics Inc. (herinafter referred to as
deCODE), have made a contract with a third party (hereinafter referred to as the
Purchaser) on the sale of the Research Project, its results and findings. deCODE
shall never be considered the purchaser of the Project in the understanding of
this Contract.

3.3. FIXED PAYMENTS FROM IE TO RTCOPD/SH/HJARTAVERND IN RELATION TO THE SALE OF
THE RESEARCH PROJECT

IE shall pay RTCOPD/SH/Hjartavernd [CONFIDENTIAL TREATMENT REQUESTED] on the
effective date of this Contract. Thereafter, IE shall pay an annual amount of
[CONFIDENTIAL TREATMENT REQUESTED] until a total of [CONFIDENTIAL TREATMENT
REQUESTED] have been paid including the initial payment.

Thus, the payments from IE under this chapter shall take place on the following
payment dates:

[CONFIDENTIAL TREATMENT REQUESTED]

In the event that the Research Project ends within five years from the signature
of this Contract, upon achieving the objective of the Research Project, IE shall
pay the remaining amount so that a total of [CONFIDENTIAL TREATMENT REQUESTED]
shall have been paid, pursuant to this chapter. Payments under this chapter are
additional and independent to conditional payments under Chapter 3.4.

In the event that IE/deCODE enters into a contract of sale, one or more, on the
results of the Research Project, in addition to the contract of sale already
made with a third party on the effective date of this Contract and referred to
in Paragraph 2 of Chapter 3.2., IE and RTCOPD shall start negotiating an
agreement on fixed payments from IE to RTCOPD/SH/Hjartavernd in response to such
a contract of sale. Such payments
<PAGE>   5
shall be based on the net proceeds of IE/deCODE from the latter sale of the
results of the research, the contribution of RTCOPD and whether the sale is a
total sale of rights attached to the Research Project or only a partial sale of
such rights. Payments pursuant to this paragraph shall, however, never exceed
the total amount of payments specified in Paragraph 2 of this sub-chapter.

3.4. PERFORMANCE-RELATED PAYMENTS FROM IE TO RTCOPD/SH/HJARTAVERND IN RELATION
TO THE SALE OF THE RESEARCH PROJECT
IE/deCODE have made an agreement with the Purchaser to the effect that the
Purchaser shall pay special conditional payments to IE/deCODE which shall be
totally dependent on the scientific and/or practical results achieved in the
performance of the Project. The performance-related milestones which activate
the Purchaser's obligation to pay are further specified in the contract between
IE/deCODE and the Purchaser. In the event that the above-mentioned milestones
are not achieved, no payments pursuant to this paragraph shall be made.

IE shall pay RTCOPD/SH/Hjartavernd [CONFIDENTIAL TREATMENT REQUESTED] of
payments from the Purchaser to IE/deCODE pursuant to Paragraph 1 of this
sub-chapter if success is achieved. All other payments from the Purchaser to
IE/deCODE in relation to the repayment of the cash outlay of IE for the Research
Project, as defined in the contract between IE and the Purchaser, and the
Purchaser's investment in IE/deCODE shall be paid in full to IE/deCODE.

IE shall report to RTCOPD as soon as the Purchaser has confirmed that a
milestone which activates the Purchaser's obligation to pay has been achieved.
The share of RTCOPD of the milestone-related payment shall be paid when the
milestone payment from the Purchaser has been delivered to IE/deCODE. RTCOPD is
authorised by IE/deCODE to seek the confirmation of the companies' auditor,
concurrently with the quarterly statement, of whether and when a milestone
payment has been achieved in relation to the Research Project.

Performance-related payments from IE to RTCOPD pursuant to this sub-chapter
shall also be calculated from the performance-related payments from purchasers
to IE/deCODE as regards contracts of sale other than the contract specified in
Paragraph 2 of Chapter 3.2. and which may be made after the effective date of
this Contract on the results of the Research Project, cf. Paragraph 4 of
Sub-Chapter 3.3.

3.5. PROVISO ON CO-OPERATION WITH RESEARCH PARTIES UNRELATED TO RTCOPD
The right of receiving payments pursuant to Sub-Chapters 3.3 and 3.4 is based on
the assumption that IE will not pay other parties than RTCOPD and institutions
which employ individual parties within RTCOPD for their contribution to the
Research Project and expertise to which it is necessary to gain access for the
achievement of the objectives of the Research Project in the view of the
Executive Committee. If the Executive Committee is of the opinion that it is
necessary to enter into co-operation with more parties pursuant to the above,
the provisions of Sub-Chapters 3.3. and 3.4. shall be reviewed on the basis that
the total payments from IE to RTCOPD and/or institutions related to them, on the
one hand, and a third party, on the other hand, shall remain unchanged from the
payments described in Chapters 3.3 and 3.4.
<PAGE>   6
3.6. ARRANGEMENT OF PAYMENTS AND DISPOSAL OF PAYMENTS FROM IE PURSUANT TO
CHAPTERS 3.3 AND 3.4., CF. ALSO CHAPTER 7.3 OF THE INSTITUTIONS AGREEMENT
All payments from IE to RTCOPD/SH/Hjartavernd pursuant to chapters 3.3. and 3.4.
of this Contract shall be divided and paid in the following manner, cf. the
provisions of Chapter 7.3. of the Institutions Agreement and the provisions of
the Institutions Agreement in other respects, cf. also the framework agreement
between IE and Hjartavernd. All payments to RTCOPD/SH pursuant to the above
shall be paid into a special fund in the custody of SH, cf. the final clause of
Paragraph 2 of Chapter 7.3 of the Institutions Agreement. The following division
of payments is based on an agreement between the parties to this Contract as
well as their evaluation of the contribution of each party to the Research
Project. According to the above, the division of payments shall be as follows:

[CONFIDENTIAL TREATMENT REQUESTED]

The above division of payments shall not be binding for IE before such time as
all health-care institutions participating in the Research Project have
confirmed this Contract by signature, cf. Paragraph 2 of Chapter 2 of the
Institutions Agreement.

The following paragraph applies only to the allocation of funds raised by
parties within RTCOPD who are employed by SH.

All funds raised by RTCOPD pursuant to the provisions of Chapters 3.3. and 3.4.
of this Contract the application of which will be governed by RTCOPD, pursuant
to the Institutions Agreement and further agreement between RTCOPD and SH, shall
be allocated by RTCOPD to the research of pulmonary diseases. Such funds may not
be used for any other purposes. All funds which will be in the custody of RTCOPD
pursuant to the above shall be put into the Research Fund of the Faculty of
Pulmonary Research of the State Hospitals, which operates according to an
organisational charter approved by the Ministry of Justice, cf. the Foundations
Act, currently Act No. 19/1988. The organisational charter is attached to this
Research Contract as Annex D. The accounting of the above fund shall be the
responsibility of SH. The financial management of the fund can, upon further
agreement, be in the hands of the its board of directors, according to the
provisions of its articles of association.

                                    CHAPTER 4
                            MANAGEMENT AND LIABILITY
Decisions relating to the performance of the Research Project shall be made
jointly by RTCOPD and IE. A special Executive Committee shall be established to
supervise the performance of the Research Project. Initially, each party to the
Contract shall appoint two members to the Executive Committee. More members may
be added later, provided that there will an equal number of members from, on the
one hand, RTCOPD and, on the other hand, IE in the Committee. The Chief
Supervisor of the Research Project shall be elected from among the members of
the Executive Committee. It is also the responsibility of the Committee to
define the objectives of the Research Project and set forth the professional
requirements which the parties to this Contract agree to be satisfactory for its
performance. The Executive Committee
<PAGE>   7
shall also seek a settlement of disputes which may arise between the parties to
the Contract.

Plans on incurring expenses in relation to the Research Project shall be
submitted in advance and confirmed by the Executive Committee. When applicable,
the Executive Committee may enter into agreements with health-care institutions
or other qualified parties on the use of the their manpower and facilities for
performing individual tasks in relation to the clinical part of the research. In
November each year the Executive Committee shall prepare a budget for the
Research Project in the following calendar year.

The Executive Committee shall supervise the processing of data and the
publication of conclusions in accordance with the rules of Chapter 5.

RTCOPD and individuals within the Team shall not be financially responsible to
IE or other parties with interests in the achievement of the commercial or
financial objectives of the research.

IE shall pay the expense of procuring liability insurance for individuals within
RTCOPD who are employed by SH on the effective date of this Contract as well as
staff employed by them. This applies to all work undertaken by these parties in
the interest of the Research Project.

                                    CHAPTER 5
              HANDLING, PROCESSING AND COMMUNICATION OF INFORMATION
The parties to this Contract undertake to maintain all personal information in
confidence in accordance with statutory provisions. The parties to this Contract
undertake to comply with the instructions of the Data Protection Commission and,
as applicable, the special representative (inspector) of the Data Protection
Commission on the handling and processing of such data, as well as with the
instructions and conditions of the Science Ethics Committee, which operates
pursuant to the Act on Patients' Rights. This entails that only information
which the Data Protection Commission has authorised access to may be used.

The findings of the Research Project shall be immediately published as soon as
they fulfil scientific requirements and are fit for publication. However, IE or
the Purchaser of the Project may have the publication of the findings postponed
for 90 days, if necessary to ensure patents and other rights of ownership
related to the findings of the Project.

The Executive Committee of the Project shall decide in advance who shall be
Chief Supervisor of the Research Project. As a rule, the first cited author of
scientific articles shall be Chief Supervisor. The order of authors shall be in
accordance with current rules in the international scientific community.

The parties to this Contract promise mutual confidentiality as regards
information in relation to the substance of this Contract, business plans, the
progress of the Project and its conclusions. Information of this kind may not be
communicated to an outside party without the consent of both parties.
<PAGE>   8
                                    CHAPTER 6
                  LIMITATION ON CO-OPERATION WITH OTHER PARTIES

RTCOPD and individuals within the Team promise to work neither jointly nor
separately with other parties on research into the inheritability of COPD during
the Research Project. In the event that the Research Project leads to a
discovery which has financial significance for IE, RTCOPD and individual parties
within the Team promise not to enter into co-operation with other parties on the
part of the Research Project which led to the discovery for five years
immediately following the conclusion of the Project as defined in this Contract.
On the other hand, if the Research Project does not lead to such an achievement,
individual parties within the co-operating team have the right to enter into
co-operation with other parties on research into the inheritability of COPD
after the Research Project has ended.

IE promises not to begin collaboration with other parties in the research of the
inheritability of COPD during the Research Project, unless the Executive
Committee considers such collaboration necessary to achieve the objective of the
Research Project. If the addition of new co-operating parties to the Research
Project is considered necessary, the Executive Committee shall be in charge of
the selection of such a party. In the event of a dispute within the Executive
Committee, RTCOPD shall have the final decision on the selection of additional
co-operating parties. The provisions of this Paragraph shall not, however,
prevent IE from collaborating in the field of the Research Project with parties
that have negotiated the purchase of the Research Project, its conclusions or
findings, provided that such actions do not reduce the right to payments
pursuant to Chapter 3.

                                    CHAPTER 7
                   TERM OF THE CONTRACT AND PROJECT COMPLETION

The effective date of this Contract shall be the date (hereinafter referred to
as the effective date) on which this Contract has been both signed by the
parties to the Contract and confirmed in signature by SH in accordance with
Paragraph 2 of Chapter 2 of the Institutions Agreement.

The Research Project shall have a duration of five years immediately following
the effective date, unless completed before such time in the view of the
Executive Committee. If either party has materially defaulted on the Contract,
the other party may terminate the Contract. In the event of a dispute on the
right of the parties to terminate the Contract, the settlement procedures
regarding such dispute shall be pursuant to Chapter 8.

The return of all original materials of RTCOPD shall be returned to RTCOPD,
unless an agreement to the contrary is made between RTCOPD and IE, e.g. if the
materials are used in another research in the field of genetics, on the
condition that the approval of the participants and a permit from the public
authorities with the authority to permit such an arrangement have been obtained.
The return of research materials from SH on completion of the Research Project
shall be in accordance with Paragraph 5 of Chapter 6 of the Institutions
Agreement.
<PAGE>   9
In the event that either or both parties see reason to continue the co-operation
after the agreed period, this shall be negotiated separately.

Notwithstanding a cessation of the research pursuant to this Contract, whether
as a result of the completion, cancellation or termination of the Project, the
obligation of IE/deCODE to effect payments pursuant to Chapter 3.4. shall remain
intact until such time as the right of IE /deCODE to payments from the Purchaser
is cancelled each time, e.g. when a patent expires.

                                    CHAPTER 8
                             SETTLEMENT OF DISPUTES
In the event of a dispute between the parties to this Contract regarding
performance or compliance that cannot be resolved by the Executive Committee,
two persons, one from each party, shall endeavour to reach an agreement on its
settlement. If a settlement is not reached between those two persons within two
weeks of the submission of the dispute, each party to the Contract shall appoint
one arbitrator and then jointly request the appointment of an impartial third
arbitrator by the District Court of Reykjavik to assist in the resolution of the
dispute, thus forming a tribunal of three arbitrators. The arbitration tribunal
shall reach a decision in the matter within one months from the appointment of
the third arbitrator.

The cost of the work of the tribunal shall be determined by the tribunal at each
time. The work, procedure and rulings of the arbitration tribunal shall
otherwise be governed, as appropriate at any time, by Act No. 53/1989 on
Contractual Arbitration.

Notwithstanding the above provisions on arbitration, cases involving the
collection of payments under this Contract which are not in dispute between the
parties may be submitted to the public courts. The same applies to cases of
financial claims made by one party against the other, based on rulings of the
arbitration tribunal regarding non-performance or breach by the latter of this
Contract. Such cases shall be submitted to the District Court of Reykjavik.
<PAGE>   10
This Contract, which comprises 8 chapters on 9 pages, in addition to Appendices
A, B, C and D, is made in two identical copies, one copy to be held by each of
the parties to the Contract.

Reykjavik, 1 July 1999.

On behalf of the Research                     On behalf of Islensk
Team for COPD                                 Erfoagreining ehf.

_____________________________________         __________________________________
[Foreign Character]orarinn                    Kari Stefansson [sign.]
Gislason [sign.] Senior Physician, SH         CEO of IE

_____________________________________         __________________________________
Andres Sigvaldason [sign.]                    Kristjan Erlendsson [sign.]
Physician, SH                                 VP for Clinical and Academic
                                              Collaborations
_____________________________________
Vilmundur Guonason [sign.]
Physician, Hjartavernd

SH hereby confirms this
Research Contract,

Reykjavik, 20 August '99

_____________________________________
Magnus Petursson [sign.]

_____________________________________

Hjartavernd hereby confirms this
Research Contract, 20 August '99

Reykjavik,

_____________________________________
Gunnar Sigurosson [sign.]

_____________________________________Exhibit 4.2

COMMON STOCK
NUMBER                                                     ____________ Shares

                               HARCOURT GENERAL
             Incorporated under the laws of the State of Delaware

 This certificate is transferable in Boston, Massachusetts or in New York, New
York

                            HARCOURT GENERAL, INC.

                                                             CUSIP 41163G 10 1

     This certifies that                  is the owner of

     Fully paid and non-assessable shares of the common stock, one dollar
($1.00) par value, of Harcourt General, Inc. (herein called the
"Corporation") transferable upon the books of the Corporation in person or by
attorney upon surrender of this certificate duly endorsed or assigned.  This
certificate and the shares represented hereby are subject to the laws of the
State of Delaware, and to the Restated Certificate of Incorporation and the
By-Laws of the Corporation, as amended from time to time (copies of which are
on file with the Transfer Agents).  This certificate is not valid until
countersigned by a Transfer Agent and registered by a Registrar.

     In Witness Whereof, Harcourt General, Inc. has caused its facsimile
corporate seal and the facsimile signatures of its duly authorized officers
to be hereunto affixed.

Dated:

                               Richard A. Smith
                               Chairman

Countersigned and Registered:
By BankBoston, N.A.
Transfer Agent and Registrar

     Authorized Signature                Eric Geller
                                         Secretary

<PAGE>

     The following abbreviations, when used in the inscription on the face of
this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:

     TEN COM   - as tenants in common
     TEN ENT   - as tenants by the entireties
     JT TEN    - as joint tenants with right of survivorship and not as
tenants in common
     UNIF GIFT MIN ACT -  _________ (Cust) Custodian _________ (Minor) under
                          Uniform Gifts to Minors Act _________(State)

    Additional abbreviations may also be used though not in the above list.

     For Value Received, ___________ hereby sell, assign and transfer unto

_____________ (Please insert social security or other identifying number of
assignee)

------------------------------------------------------------------------------
 (Please print or typewrite name and address, including zip code, of assignee)

------------------------------------------------------------------------------

------------------------------------------------------------------------------

_____________________________________________________________________ Shares
of the capital stock represented by the within Certificate, and do hereby
irrevocably constitute and appoint __________________________ Attorney to
transfer the said stock on the books of the within named Corporation with full
power of substitution in the premises.

Dated __________________________

                    ______________________________________________________
                    NOTICE:    The signature to this assignment must
                               correspond with the name as written on the face
                               of the certificate in every particular, without
                               alteration or enlargement or any change
                               whatever.

     SIGNATURE(S) GUARANTEED: _________________________________________
                               The signature(s) should be guaranteed by an
                               eligible guarantor institution (banks,
                               stockbrokers, savings and loan associations and
                               credit unions with membership in an approved

                                      -2-

<PAGE>

                               signature guarantee medallion program),
                               pursuant to S.E.C. Rule 17Ad-15.

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}]]